Quest Pharmatech Inc

Quest PharmaTech, Inc. is a biotechnology company, which develops and commercializes antibody based immunotherapeutic products for cancer. The company is headquartered in Edmonton, Alberta. The firm is developing products to improve the quality of life. The firm is also developing a proprietary MAb AR 9.6 targeting truncated MUC16 as theranostic agents for cancer. The firm has a 42.5% ownership interest in OncoQuest Inc. (OncoQuest), a Canadian biotechnology company developing combinatorial immunotherapy products for the treatment of cancer. OncoQuest’s technology platform included a panel of tumor antigen-specific monoclonal antibodies of the immunoglobulin G (IgG) and E (IgE) class targeting CA125, MUC1, PSA, Her2/neu, CA 19.9 and TAG72; and the application of combinatorial immunotherapy to enhance tumor specific immunity and clinical outcome. The company also has a 23% ownership interest in OncoVent Co., Ltd. (OncoVent), which is developing antibody-based immunotherapeutic products for cancer for the Greater China territory.